Date: 2016-08-22
Type of information: Production agreement
Compound: bispecific 3F8-antibody
Company: Y-mAbs Therapeutics (USA - NY) Abzena (UK)
Therapeutic area: Cancer - Oncology
Type agreement: production manufacturing
Action mechanism: bispecific antibody
Disease:
Details: * On August 22, 2016, Y-mAbs Therapeutics, announced that it has executed an agreement for technology transfer and scale-up process runs for its first bispecific 3F8-antibody compound at Abzena. YmAbs expects to bring the bispecific antibody in clinical development against GD2 positive solid tumors, such as Ewing’s Sarcoma. YmAbs’ Chief Executive Officer, Dr. Claus Møller, said, "We expect to take delivery of cGMP drug product for our planned clinical trials in first half of 2017, potentially allowing for a US IND filing to the FDA in the third quarter 2017, and we are committed to making this potent immunotherapy product available to patients worldwide."
Financial terms:
Latest news:
